Biopharma companies that are focused on cell therapies have reported promising clinical trial results in their ability to treat acute respiratory distress syndrome (ARDS), a condition that has shown to be a significant contributor to higher mortality in COVID-19 cases.
The top two biggest money biopharma deals in 2020 occurred in June, putting the month ahead of all other months for the year in terms of deal values and volumes.
With an increasing number of neurological manifestations being reported in patients suffering from COVID-19 infection, the need for therapies to treat those conditions as well as other major CNS disorders has, once again, been highlighted. That may be one of the reasons why investors have turned their attention to the space once again, with several members of the BioWorld Neurological Diseases index enjoying an uptick in their share valuations.
The number of clinical trials initiated each year has continued to grow every year over the last decade, sans a slight decrease in 2013, according to data presented in a webcast facilitated by Applied Clinical Trials.
Although the FDA suggested in May that it might have trouble meeting PDUFA dates due to the COVID-19 pandemic, the 30 approvals of biologics and drugs handed down in June 2020 is the highest number for a single month in the past five years.
RSS
